- Home
- RCS vs CRMD Comparison
RCS vs CRMD Comparison
Compare RCS & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCS
- CRMD
- Stock Information
- Founded
- RCS 1994
- CRMD 2006
- Country
- RCS United States
- CRMD United States
- Employees
- RCS N/A
- CRMD N/A
- Industry
- RCS Investment Managers
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- RCS Finance
- CRMD Health Care
- Exchange
- RCS Nasdaq
- CRMD Nasdaq
- Market Cap
- RCS 279.8M
- CRMD 279.7M
- IPO Year
- RCS N/A
- CRMD 2010
- Fundamental
- Price
- RCS $7.80
- CRMD $8.90
- Analyst Decision
- RCS
- CRMD Strong Buy
- Analyst Count
- RCS 0
- CRMD 5
- Target Price
- RCS N/A
- CRMD $12.60
- AVG Volume (30 Days)
- RCS 141.1K
- CRMD 999.4K
- Earning Date
- RCS 01-01-0001
- CRMD 11-12-2024
- Dividend Yield
- RCS 10.12%
- CRMD N/A
- EPS Growth
- RCS N/A
- CRMD N/A
- EPS
- RCS N/A
- CRMD N/A
- Revenue
- RCS N/A
- CRMD $806,119.00
- Revenue This Year
- RCS N/A
- CRMD N/A
- Revenue Next Year
- RCS N/A
- CRMD $206.77
- P/E Ratio
- RCS N/A
- CRMD N/A
- Revenue Growth
- RCS N/A
- CRMD 2107.40
- 52 Week Low
- RCS $4.51
- CRMD $2.57
- 52 Week High
- RCS $6.31
- CRMD $9.03
- Technical
- Relative Strength Index (RSI)
- RCS 72.59
- CRMD 81.15
- Support Level
- RCS $7.61
- CRMD $7.88
- Resistance Level
- RCS $7.70
- CRMD $8.44
- Average True Range (ATR)
- RCS 0.12
- CRMD 0.45
- MACD
- RCS -0.01
- CRMD 0.06
- Stochastic Oscillator
- RCS 89.36
- CRMD 94.06
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with this objective.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.